We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Werfen to Acquire Transfusion and Transplant Diagnostics Innovator for Around USD 2 Billion

By LabMedica International staff writers
Posted on 08 Nov 2022

Werfen (Barcelona, Spain) has agreed to acquire Immucor, Inc. (Norcross, GA, USA), a privately held corporation with a global presence in transfusion and transplant in vitro diagnostics, at a purchase price of approximately USD 2 billion. The acquisition will allow Werfen to expand its portfolio of Specialized Diagnostics solutions for hospitals and clinical laboratories. The transaction is expected to close during the first half of 2023, subject to customary regulatory approvals.

"As a global leader in the research, development, manufacturing and distribution of innovative, Specialized Diagnostics solutions for hospitals and clinical laboratories, Immucor is a natural fit with our existing business model," said Marc Rubiralta, President of Werfen. "We highly value Immucor's commitment to enhancing care for all patients in need of a transfusion or transplant. This fits squarely with our long-term vision and strategy, aligns with our focus, and complements Werfen's values."

"I am confident that by combining two complementary, outstanding Specialized Diagnostics companies, Werfen will expand its global presence with greater diversification, while successfully maintaining its focus on specialization," Rubiralta added.

"Immucor's expertise and innovations in transfusion and transplant diagnostics enable us to enter new markets and will help achieve our vision to be the preferred choice of the most advanced laboratory and point-of-care customers, globally," said Carlos Pascual, CEO of Werfen. "It will be a major milestone in the future of Werfen."

"As we look to the future, we are excited to grow our impact as part of Werfen, a company that shares our long-term vision and commitment to advancing patient care globally," said Avi Pelossof, CEO of Immucor. "As the value of diagnostics in the healthcare system grows, we are confident that Immucor will continue to innovate and succeed under Werfen's ownership."

Related Links:
Werfen
Immucor, Inc. 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Technology

view channel
Image: Pictorial representation of the working principle of a functionalized Carbon Dots CDs and EB based Func sensor (Photo courtesy of Toppari/University of Jyväskylä)

Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection

Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.